Cryptococcosis - Pipeline Insight, 2024

This “Cryptococcosis - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cryptococcosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cryptococcosis Understanding

Cryptococcosis: Overview

Cryptococcosis is caused by a fungus known as Cryptococcosis neoformans. The infection may be spread to humans through contact with pigeon droppings or unwashed raw fruit. Contact with an infected individual may also spread the infection. Individuals with disorders characterized by lowered immunity (for instance, HIV infection) are at high risk for contracting these infections. Cryptococcosis may appear in various forms depending on how the infection is acquired. In most cases, the infection begins in the lungs (pulmonary form) and may then spread to the brain, urinary tract, skin, and/or bones (disseminated form).

Cryptococcosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryptococcosis pipeline landscape is provided which includes the disease overview and Cryptococcosis treatment guidelines. The assessment part of the report embraces, in depth Cryptococcosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryptococcosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cryptococcosis R&D. The therapies under development are focused on novel approaches to treat/improve Cryptococcosis.

Cryptococcosis Emerging Drugs Chapters

This segment of the Cryptococcosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cryptococcosis Emerging Drugs

MAT 2203: Matinas Bio Pharma MAT2203 is an orally-administered formulation of amphotericin B (a broad spectrum fungicidal agent) utilizing Matinas’ proprietary lipid nano-crystal (“LNC”) delivery technology platform. The Company’s LNC delivery platform utilizes lipid nano-crystals which can encapsulate small molecules, nucleic acid polymers such as oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patientswithCryptococcosis.

Cryptococcosis: Therapeutic Assessment

This segment of the report provides insights about the different Cryptococcosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cryptococcosis

There are approx. 4+ key companies which are developing the therapies for Cryptococcosis. The companies which have their Cryptococcosis drug candidates in the most advanced stage, i.e. phase II include, Matinas BioPharma.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cryptococcosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cryptococcosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryptococcosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryptococcosis drugs.

Cryptococcosis Report Insights

• Cryptococcosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cryptococcosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cryptococcosis drugs?
• How many Cryptococcosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryptococcosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cryptococcosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cryptococcosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Matinas BioPharma
• Mycovia Pharmaceuticals
• Aparna Biosciences
• FUJIFILM Toyama Chemical
• TGV Therapeutics
• Amplyx Pharmaceuticals

Key Products

• MAT 2203
• TC PMY 123

Research programme: fungal infection therapies- ATI 2307

• MYC 053
• APX 2039

This product will be delivered within 1-3 business days.